Bod Australia Ltd (BOD) AI Stock Analysis

• Market Cap: AU$4.26M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.39
• Revenue Growth: -49.04%
• EPS Growth: 32.85%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.04
• Shares Outstanding: 177,338,490
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: ―

Bod Australia Ltd faces significant financial and operational challenges with declining revenues, persistent losses, and negative equity. Technical analysis indicates overbought conditions without clear upward momentum, while valuation metrics are unfavorable due to a negative P/E ratio. These factors suggest a high-risk profile, resulting in a low overall stock score.

Bod Australia Ltd Business Overview & Revenue Model

Company Description

Bod Australia Ltd (BOD) is an innovative health and wellness company specializing in the development and manufacture of premium consumer products. Operating primarily in the sectors of cannabis, hemp, and natural medicines, BOD focuses on delivering high-quality, scientifically-backed products that enhance the wellbeing of consumers. The company's core offerings include nutraceuticals, skincare products, and over-the-counter pharmaceuticals, tailored to meet the growing demand for natural and effective health solutions.

How the Company Makes Money

Bod Australia Ltd generates revenue through a diversified business model centered around the production and sale of health and wellness products. The company earns money primarily by selling its range of nutraceuticals and skincare products through various distribution channels, including retail partnerships, online sales, and direct-to-consumer platforms. Additionally, BOD benefits from strategic partnerships and licensing agreements with leading companies in the pharmaceutical and cosmetics industries, which expand its market reach and enhance its product offerings. Further contributing to its revenue are research and development collaborations that potentially lead to licensing deals and royalties. BOD's focus on high-quality, scientifically-proven products helps it maintain a competitive edge and attract a loyal customer base, thereby driving its financial performance.

Bod Australia Ltd Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
875.56K	1.72M	3.42M	6.58M	5.01M
	Gross Profit
-2.08M	-3.08M	498.15K	2.66M	1.14M
	EBIT
-4.96M	-7.45M	-5.89M	-4.11M	-3.67M
	EBITDA
-8.03M	-7.98M	-5.48M	-3.95M	-4.00M
	Net Income Common Stockholders
-6.41M	-7.95M	-5.41M	-4.23M	-4.82M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
434.40K	2.03M	3.67M	8.05M	6.39M
	Total Assets
2.31M	3.50M	5.31M	10.35M	8.91M
	Total Debt
1.83M	963.13K	0.00	0.00	0.00
	Net Debt
1.40M	-1.07M	-3.67M	-8.05M	-6.39M
	Total Liabilities
7.63M	4.21M	1.85M	1.69M	4.11M
	Stockholders Equity
-5.32M	-703.36K	3.47M	8.66M	4.81M
Cash Flow		Free Cash Flow
-928.17K	-5.83M	-4.38M	-5.86M	-3.68M
	Operating Cash Flow
-913.98K	-5.68M	-4.18M	-5.83M	-3.22M
	Investing Cash Flow
-1.94M	-289.61K	-207.44K	-26.87K	-463.58K
	Financing Cash Flow
764.83K	4.14M	0.00	7.50M	7.23M

Bod Australia Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BOD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -133.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BOD.

Bod Australia Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.19B	3.33	-45.04%	2.83%	17.58%	-0.66%
EXL	46 Neutral	$3.09M	―	-21.29%	―	80.87%	82.44%
AVE	46 Neutral	AU$15.87M	―	-64.72%	―	139.19%	33.33%
BOD	39 Underperform	AU$4.26M	―		―	-49.04%	32.85%
CAN	39 Underperform	$9.02M	―	-164.01%	―	-18.80%	-46.65%
AGH	37 Underperform	AU$19.74M	―	-218.38%	―	-14.30%	29.69%

Bod Australia Ltd Corporate Events

Bod Science Limited Announces Change in Principal Place of Business

Bod Science Limited has announced a change in its registered office and principal place of business to a new address in Sydney, Australia. This move, approved by the Deed Administrator, reflects the company’s ongoing restructuring efforts under a Deed of Company Arrangement. The change is part of Bod’s strategic initiatives to strengthen its operational framework and potentially improve its market positioning.

Bod Science Limited Announces Change in Company Secretary

Bod Science Limited has announced a change in its company secretary, with Carlie Hodges resigning and Joanne Patterson being appointed as her replacement. This change occurs as the company continues to operate under a Deed of Company Arrangement, reflecting ongoing restructuring efforts. The appointment of a new company secretary may impact the company’s administrative operations and stakeholder relations as it navigates its current financial and strategic challenges.

Bod Science Limited Advances Corporate Restructuring with Biortica Acquisition

Bod Science Limited has entered into a Deed of Company Arrangement with Biortica Agrimed Limited, which includes a Share Purchase Agreement to acquire Biortica’s shares. The completion of this arrangement is contingent on meeting certain conditions, including shareholder approvals and compliance with ASX requirements. The company reported a net cash inflow from operating activities of $42k for Q3 FY2025, with customer receipts increasing significantly due to new product introductions. The arrangement and financial updates reflect Bod’s strategic efforts to stabilize and grow its operations amid ongoing corporate restructuring.

Bod Science Limited Extends DOCA Period Amid ASX Compliance Delays

Bod Science Limited is undergoing a Deed of Company Arrangement (DOCA) with Biortica Agrimed Limited, which was executed in April 2024. The DOCA period has been extended to June 2025 due to delays in meeting ASX requirements, and an extraordinary general meeting will be scheduled once conditions are met.